Table of Content

1 INTRODUCTION 36
1.1 STUDY OBJECTIVES 36
1.2 MARKET DEFINITION 36
1.3 STUDY SCOPE 37
1.3.1 MARKETS COVERED & REGIONAL SCOPE 37
1.3.2 INCLUSIONS & EXCLUSIONS 38
1.3.3 YEARS CONSIDERED 39
1.4 CURRENCY CONSIDERED 40
1.5 STAKEHOLDERS 40
1.6 SUMMARY OF CHANGES 40
2 RESEARCH METHODOLOGY 42
2.1 RESEARCH DATA 42
2.1.1 SECONDARY DATA 43
2.1.1.1 Key data from secondary sources 44
2.1.2 PRIMARY DATA 44
2.1.2.1 Key data from primary sources 46
2.1.2.2 Insights from primary experts 47
2.2 MARKET SIZE ESTIMATION 48
2.3 DATA TRIANGULATION 52
2.4 MARKET SHARE ESTIMATION 53
2.5 RESEARCH ASSUMPTIONS 53
2.6 LIMITATIONS 53
2.6.1 METHODOLOGY-RELATED LIMITATIONS 53
2.6.2 SCOPE-RELATED LIMITATIONS 53
2.7 RISK ASSESSMENT 54
3 EXECUTIVE SUMMARY 55
4 PREMIUM INSIGHTS 61
4.1 BIOSIMULATION MARKET OVERVIEW 61
4.2 ASIA PACIFIC: BIOSIMULATION MARKET, BY REVENUE MODEL AND COUNTRY (2023) 62
4.3 BIOSIMULATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 63
4.4 BIOSIMULATION MARKET: REGIONAL MIX (2024?2029) 63
4.5 BIOSIMULATION MARKET: DEVELOPED VS. EMERGING ECONOMIES 64
5 MARKET OVERVIEW 65
5.1 INTRODUCTION 65
5.2 MARKET DYNAMICS 65
5.2.1 DRIVERS 66
5.2.1.1 Increasing R&D investments in pharmaceutical and biotechnology industries 66
5.2.1.2 Growing adoption of biosimulation software by regulatory bodies 66
5.2.1.3 Integration of technologically advanced Quantitative Systems Pharmacology (QSP) 67
5.2.1.4 Need to curtail drug discovery and development costs 67
5.2.1.5 Growth in biologics and biosimilars markets 67
5.2.2 RESTRAINTS 68
5.2.2.1 Lack of standardization 68
5.2.2.2 Data availability and quality 68
5.2.3 OPPORTUNITIES 69
5.2.3.1 Emerging applications 69
5.2.3.2 Use of biosimulation solutions for pediatric drug development 69
5.2.4 CHALLENGES 70
5.2.4.1 Difficulties in matching complexity of biological systems and processes 70
5.2.4.2 Shortage of biosimulation and modeling experts 70
5.3 ECOSYSTEM ANALYSIS 70
5.3.1 SOFTWARE PROVIDERS 70
5.3.2 PHARMACEUTICAL & BIOTECH COMPANIES 70
5.3.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) 71
5.3.4 REGULATORY BODIES 71
5.3.5 ACADEMIC & RESEARCH INSTITUTIONS 71
5.4 CASE STUDY ANALYSIS 72
5.4.1 CASE STUDY 1: OPTIMIZING ASCIMINIB DEVELOPMENT THROUGH ADVANCED PBPK MODELING 72
5.4.2 CASE STUDY 2: COMPUTATIONAL DISCOVERY OF SELECTIVE WEE1 INHIBITORS FOR CANCER 73
5.4.3 CASE STUDY 3: EFFICIENT CLINICAL TRIAL UTILIZING SCALE MANAGEMENT EXPERTISE 73
5.5 VALUE CHAIN ANALYSIS 74
5.6 PORTER’S FIVE FORCES ANALYSIS 76
5.6.1 BARGAINING POWER OF SUPPLIERS 77
5.6.2 BARGAINING POWER OF BUYERS 77
5.6.3 THREAT OF SUBSTITUTES 77
5.6.4 THREAT OF NEW ENTRANTS 77
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 77
5.7 REGULATORY ANALYSIS 78
5.7.1 REGULATORY LANDSCAPE 78
5.7.1.1 North America 78
5.7.1.2 Europe 79
5.7.1.3 Asia Pacific 79
5.7.1.4 Latin America 80
5.7.1.5 Middle East & Africa 80
5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
5.8 PATENT ANALYSIS 83
5.8.1 PATENT PUBLICATION TRENDS FOR BIOSIMULATION 83
5.8.2 JURISDICTION AND TOP APPLICANT ANALYSIS 83
5.9 TECHNOLOGY ANALYSIS 84
5.9.1 KEY TECHNOLOGIES 84
5.9.1.1 Mathematical modeling 84
5.9.1.2 Software platforms 85
5.9.1.3 Quantitative systems pharmacology (QSP) 85
5.9.2 COMPLEMENTARY TECHNOLOGIES 85
5.9.2.1 Data analytics 85
5.9.2.2 Machine learning and AI 85
5.9.3 ADJACENT TECHNOLOGIES 85
5.9.3.1 In silico trials 85
5.10 INDUSTRY TRENDS 86
5.10.1 DISCOVERY OF BIOMARKERS 86
5.10.2 ADOPTION IN PERSONALIZED MEDICINE 86
5.11 PRICING ANALYSIS 86
5.11.1 INDICATIVE PRICING ANALYSIS OF KEY PLAYERS, BY OFFERING, 2023 87
5.11.2 AVERAGE SELLING PRICE TREND, BY REGION (QUALITATIVE) 87
5.12 KEY CONFERENCES & EVENTS, 2024–2025 88
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 88
5.13.1 BUYING CRITERIA 89
5.14 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 90
5.15 END-USER ANALYSIS 90
5.15.1 UNMET NEEDS 90
5.15.2 END-USER EXPECTATIONS 91
5.16 INVESTMENT AND FUNDING SCENARIO 92
5.17 IMPACT OF AI/GEN AI ON BIOSIMULATION MARKET 92
5.17.1 KEY USE CASES 93
5.17.2 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 94
5.17.2.1 Case study 94
5.17.2.2 Bioinformatics market 95
5.17.2.3 Drug discovery services market 95
5.17.2.4 Drug discovery informatics market 95
5.17.3 USER READINESS & IMPACT ASSESSMENT 95
5.17.3.1 User readiness 95
5.17.3.1.1 Pharmaceutical & biotechnology companies 95
5.17.3.1.2 Contract research organizations 96
5.17.3.2 Impact assessment 96
5.17.3.2.1 User A: Pharmaceutical & biotechnology companies 96
5.17.3.2.1.1 Implementation 96
5.17.3.2.1.2 Impact 96
5.17.3.2.2 User B: Academic & research institutes 97
5.17.3.2.2.1 Implementation 97
5.17.3.2.2.2 Impact 97
6 BIOSIMULATION MARKET, BY OFFERING 98
6.1 INTRODUCTION 99
6.2 SOFTWARE 99
6.2.1 STANDALONE MODULES 101
6.2.1.1 Molecular modeling & simulation software 102
6.2.1.1.1 Growing importance of molecular modeling & simulation
in drug discovery and development to accelerate market growth 102
6.2.1.2 PK/PD modeling & simulation software 103
6.2.1.2.1 Pivotal role in early drug development phase to boost market growth 103
6.2.1.3 PBPK modeling & simulation software 104
6.2.1.3.1 Widespread use by regulatory bodies to drive PBPK modeling & simulation software market 104
6.2.1.4 Toxicity prediction software 105
6.2.1.4.1 Pressing need for toxicity prediction in drug discovery and development is driving the market 105
6.2.1.5 Clinical trial simulation software 106
6.2.1.5.1 High failure rate of clinical trials to accelerate growth 106
6.2.1.6 Other biosimulation software 107
6.2.2 INTEGRATED SOFTWARE SUITES/PLATFORMS 108
6.2.2.1 Need for efficient R&D tools to accelerate growth of integrated platforms 108
6.3 SERVICES 109
6.3.1 CONSULTING & ADVISORY 111
6.3.1.1 Need to focus on core competencies to drive need for consulting
& advisory services 111
6.3.2 IMPLEMENTATION, TRAINING, AND SUPPORT 112
6.3.2.1 Need for well-trained professionals and experts to accelerate market growth 112
6.3.3 DATA ANALYSIS & INTERPRETATION 113
6.3.3.1 Accurate and precise interpretation of data to drive need for data analysis & interpretation services 113
7 BIOSIMULATION MARKET, BY APPLICATION 114
7.1 INTRODUCTION 115
7.2 DRUG DISCOVERY 115
7.2.1 TARGET IDENTIFICATION & VALIDATION 117
7.2.1.1 Need for identification of optimal targets in drug discovery to
drive market 117
7.2.2 LEAD IDENTIFICATION & OPTIMIZATION 118
7.2.2.1 Crucial role in facilitating viable drug discovery to accelerate
market growth 118
7.3 DRUG DEVELOPMENT 119
7.3.1 PRECLINICAL TESTING 120
7.3.1.1 PK/PD 122
7.3.1.1.1 Critical role of PK/PD studies in drug development to
drive market 122
7.3.1.2 ADME/Toxicology 123
7.3.1.2.1 Growing role in selection of potent drug molecules to
boost market growth 123
7.3.2 CLINICAL TRIALS 124
7.3.2.1 Phase I 125
7.3.2.1.1 Growing need to ease decision-making process to drive segmental growth 125
7.3.2.2 Phase II 126
7.3.2.2.1 Efficiency in dose assessment and product efficacy to
drive growth 126
7.3.2.3 Phase III 127
7.3.2.3.1 Need to curtail large costs involved in trials to propel demand 127
7.3.2.4 Phase IV/Post-marketing surveillance 128
7.3.2.4.1 Ability to assist researchers in process innovation and decision support to drive adoption 128
7.4 DISEASE MODELING 129
7.4.1 CAPABILITY TO PREDICT DISEASE DYNAMICS AND INFORM THERAPEUTIC STRATEGIES TO DRIVE MARKET GROWTH 129
7.5 MANUFACTURING & SUPPLY CHAIN MANAGEMENT 130
7.5.1 PRODUCTION PLANNING & OPTIMIZATION 132
7.5.1.1 Need for proper production planning and execution to drive
market growth 132
7.5.2 QUALITY CONTROL & PROCESS MONITORING 133
7.5.2.1 Adherence to maintaining product quality to fuel market growth 133
7.5.3 DEMAND FORECASTING & INVENTORY MANAGEMENT 134
7.5.3.1 Need to forecast demand effectively to drive market growth 134
7.5.4 RISK MANAGEMENT & CONTINGENCY PLANNING 135
7.5.4.1 Need to maintain operational continuity to support market growth 135
7.5.5 OTHER MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS 136
7.6 OTHER APPLICATIONS 137
8 BIOSIMULATION MARKET, BY THERAPEUTIC AREA 138
8.1 INTRODUCTION 139
8.2 ONCOLOGY 139
8.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS TO DRIVE MARKET GROWTH 139
8.3 CARDIOVASCULAR DISEASES 140
8.3.1 RISING NEED FOR DRUGS TO TREAT CARDIOVASCULAR DISEASES
TO BOOST MARKET 140
8.4 NEUROLOGICAL DISORDERS 141
8.4.1 NEED TO BOOST DRUG DISCOVERY AND DEVELOPMENT FOR NEUROLOGICAL DISORDERS TO SUPPORT MARKET GROWTH 141
8.5 INFECTIOUS DISEASES 142
8.5.1 RISING EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITY 142
8.6 OTHER THERAPEUTIC AREAS 143
9 BIOSIMULATION MARKET, BY REVENUE MODEL 145
9.1 INTRODUCTION 146
9.2 LICENSE-BASED MODELS 146
9.2.1 LICENSE-BASED MODELS TO ACCOUNT FOR LARGEST SHARE OF MARKET 146
9.3 SUBSCRIPTION-BASED MODELS 147
9.3.1 SUBSCRIPTION-BASED MODELS TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 147
9.4 SERVICE-BASED MODELS 148
9.4.1 SPECIALIZED SIMULATION EXPERTISE WITH SERVICE-BASED MODELS
TO SUPPORT ADOPTION 148
9.5 PAY-PER-USE MODELS 149
9.5.1 RISING DEMAND FOR FLEXIBLE BIOSIMULATION SOLUTIONS WITHOUT UPFRONT COSTS TO SUPPORT MARKET GROWTH 149
10 BIOSIMULATION MARKET, BY DEPLOYMENT MODEL 151
10.1 INTRODUCTION 152
10.2 ON-PREMISE MODELS 152
10.2.1 OPTIMAL CONTROL ON DEPLOYMENT AND DATA BACKUP TO SUPPORT MARKET UPTAKE 152
10.3 CLOUD-BASED MODELS 153
10.3.1 CLOUD-BASED MODEL TO EXPERIENCE HIGHEST GROWTH RATE DURING FORECAST PERIOD 153
10.4 HYBRID MODELS 154
10.4.1 BALANCED CAPABILITIES OF HYBRID BIOSIMULATION MODELS
TO ACCELERATE ADOPTION 154
11 BIOSIMULATION MARKET, BY END USER 156
11.1 INTRODUCTION 157
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 157
11.2.1 INCREASING R&D EXPENDITURE FOR DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET 157
?
11.3 CONTRACT RESEARCH ORGANIZATIONS 158
11.3.1 RISING OUTSOURCING OF CLINICAL TRIAL ACTIVITIES TO CROS BY PHARMACEUTICAL COMPANIES TO DRIVE MARKET 158
11.4 ACADEMIC & RESEARCH INSTITUTES 159
11.4.1 FAVORABLE GOVERNMENT SUPPORT FOR RESEARCH TO SUPPORT MARKET GROWTH 159
11.5 REGULATORY BODIES 160
11.5.1 GROWING USAGE OF BIOSIMULATION SOFTWARE FOR CLINICAL TRIAL EFFICACY TO PROPEL MARKET GROWTH 160
11.6 OTHER END USERS 161
12 BIOSIMULATION MARKET, BY REGION 163
12.1 INTRODUCTION 164
12.2 NORTH AMERICA 164
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 171
12.2.2 US 171
12.2.2.1 Rising government funding for pharmaceutical R&D to drive market 171
12.2.3 CANADA 177
12.2.3.1 Increasing funding by Canadian government in healthcare to drive market 177
12.3 EUROPE 183
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 189
12.3.2 GERMANY 189
12.3.2.1 High number of sponsored clinical trials to drive uptake of biosimulation 189
12.3.3 UK 195
12.3.3.1 Investments by pharmaceutical sponsors for drug discovery services to boost market 195
12.3.4 FRANCE 200
12.3.4.1 Growing R&D pipeline for clinical trials to drive market 200
12.3.5 ITALY 206
12.3.5.1 Increasing government funds and favorable regulatory scenarios
to fuel uptake 206
12.3.6 SPAIN 211
12.3.6.1 Established network of research centers to propel market 211
12.3.7 REST OF EUROPE 217
12.4 ASIA PACIFIC 222
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 229
12.4.2 CHINA 229
12.4.2.1 Low cost of drug development and large pharmaceutical R&D base to drive market 229
12.4.3 INDIA 235
12.4.3.1 Growing pharmaceutical industry to fuel uptake of biosimulation 235
?
12.4.4 JAPAN 241
12.4.4.1 Established drug development infrastructure and biomedical research capabilities to support market growth 241
12.4.5 REST OF ASIA PACIFIC 246
12.5 LATIN AMERICA 251
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 257
12.5.2 BRAZIL 257
12.5.2.1 Advancing biosimulation in region to support market growth 257
12.5.3 MEXICO 262
12.5.3.1 Government initiatives to enhance digital health to propel
market growth 262
12.5.4 REST OF LATIN AMERICA 267
12.6 MIDDLE EAST & AFRICA 272
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 278
12.6.2 GCC COUNTRIES 279
12.6.2.1 Increase in healthcare investments to support market growth 279
12.6.3 REST OF MIDDLE EAST & AFRICA 284
13 COMPETITIVE LANDSCAPE 291
13.1 INTRODUCTION 291
13.2 KEY PLAYER STRATEGY/RIGHT TO WIN 291
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BIOSIMULATION MARKET 292
13.3 REVENUE ANALYSIS, 2019–2023 293
13.4 MARKET SHARE ANALYSIS, 2023 293
13.5 RANKING OF KEY MARKET PLAYERS 296
13.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 296
13.6.1 STARS 297
13.6.2 EMERGING LEADERS 297
13.6.3 PERVASIVE PLAYERS 297
13.6.4 PARTICIPANTS 297
13.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 299
13.6.5.1 Company footprint 299
13.6.5.2 Offering footprint 300
13.6.5.3 Application footprint 301
13.6.5.4 End-user footprint 302
13.6.5.5 Region footprint 303
13.7 COMPANY EVALUATION MATRIX: START-UP/SMES, 2023 304
13.7.1 PROGRESSIVE COMPANIES 304
13.7.2 RESPONSIVE COMPANIES 304
13.7.3 DYNAMIC COMPANIES 304
13.7.4 STARTING BLOCKS 304
13.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 306
13.8 COMPANY EVALUATION AND FINANCIAL METRICS, 2025 308
13.9 BRAND/PRODUCT COMPARISON 309
13.10 COMPETITIVE SCENARIO 310
13.10.1 PRODUCT LAUNCHES & ENHANCEMENTS 310
13.10.2 DEALS 311
13.10.3 EXPANSIONS 312
13.10.4 OTHER DEVELOPMENTS 312
14 COMPANY PROFILES 313
14.1 KEY PLAYERS 313
14.1.1 CERTARA, USA 313
14.1.1.1 Business overview 313
14.1.1.2 Products & services offered 314
14.1.1.3 Recent developments 316
14.1.1.3.1 Product launches & enhancements 316
14.1.1.3.2 Deals 318
14.1.1.3.3 Other developments 319
14.1.1.4 MnM view 319
14.1.1.4.1 Right to win 319
14.1.1.4.2 Strategic choices 319
14.1.1.4.3 Weaknesses & competitive threats 319
14.1.2 DASSAULT SYST?MES 320
14.1.2.1 Business overview 320
14.1.2.2 Products & services offered 321
14.1.2.3 Recent developments 322
14.1.2.3.1 Product launches & enhancements 322
14.1.2.3.2 Deals 323
14.1.2.3.3 Other developments 323
14.1.2.4 MnM view 324
14.1.2.4.1 Right to win 324
14.1.2.4.2 Strategic choices 324
14.1.2.4.3 Weaknesses & competitive threats 324
14.1.3 SCHR?DINGER, INC. 325
14.1.3.1 Business overview 325
14.1.3.2 Products & services offered 326
14.1.3.3 Recent developments 328
14.1.3.3.1 Deals 328
14.1.3.3.2 Other developments 329
14.1.3.4 MnM view 330
14.1.3.4.1 Right to win 330
14.1.3.4.2 Strategic choices 330
14.1.3.4.3 Weaknesses & competitive threats 330
14.1.4 SIMULATIONS PLUS 331
14.1.4.1 Business overview 331
14.1.4.2 Products & services offered 332
14.1.4.3 Recent Developments 336
14.1.4.3.1 Product Launches & Enhancements 336
14.1.4.3.2 Deals 337
14.1.4.3.3 Other developments 339
14.1.5 ADVANCED CHEMISTRY DEVELOPMENT, INC. 340
14.1.5.1 Business overview 340
14.1.5.2 Products & Services Offered 340
14.1.5.3 Recent developments 341
14.1.5.3.1 Product launches & enhancements 341
14.1.5.3.2 Deals 341
14.1.6 CHEMICAL COMPUTING GROUP ULC 342
14.1.6.1 Business overview 342
14.1.6.2 Products & services offered 342
14.1.6.3 Recent developments 343
14.1.6.3.1 Product launches & enhancements 343
14.1.6.3.2 Deals 343
14.1.6.3.3 Other developments 343
14.1.7 ROSA & CO. LLC 344
14.1.7.1 Business overview 344
14.1.7.2 Products & services offered 344
14.1.8 GENEDATA AG (A DANAHER COMPANY) 345
14.1.8.1 Business overview 345
14.1.8.2 Products & services offered 346
14.1.8.3 Recent developments 347
14.1.8.3.1 Product launches & enhancements 347
14.1.8.3.2 Deals 347
14.1.9 PHYSIOMICS PLC 348
14.1.9.1 Business overview 348
14.1.9.2 Products & services offered 349
14.1.9.3 Recent developments 350
14.1.9.3.1 Product launches & enhancements 350
14.1.9.3.2 Other developments 350
14.1.10 IN SILICO BIOSCIENCES 351
14.1.10.1 Business overview 351
14.1.10.2 Products & services offered 351
14.1.11 ALLUCENT 352
14.1.11.1 Business overview 352
14.1.11.2 Products & services offered 352
?
14.1.11.3 Recent developments 353
14.1.11.3.1 Deals 353
14.1.11.3.2 Expansions 353
14.1.11.3.3 Other developments 353
14.1.12 OPENEYE, CADENCE MOLECULAR SCIENCES 354
14.1.12.1 Business overview 354
14.1.12.2 Products & services offered 355
14.1.12.3 Recent developments 356
14.1.12.3.1 Product enhancements 356
14.1.12.3.2 Deals 356
14.1.12.3.3 Expansions 357
14.1.13 CELLWORKS GROUP, INC. 358
14.1.13.1 Business overview 358
14.1.13.2 Products & services offered 358
14.1.13.3 Recent developments 359
14.1.13.3.1 Other developments 359
14.1.14 VERISIM LIFE 360
14.1.14.1 Business overview 360
14.1.14.2 Products & services offered 360
14.1.14.3 Recent developments 361
14.1.14.3.1 Deals 361
14.1.14.3.2 Other developments 362
14.1.15 NETABOLICS 363
14.1.15.1 Business overview 363
14.1.15.2 Products & services offered 363
14.1.16 CHARNWOOD DISCOVERY 364
14.1.16.1 Business overview 364
14.1.16.2 Products & services offered 364
14.1.16.3 Recent developments 365
14.1.16.3.1 Deals 365
14.1.17 THE MATHWORKS, INC. 366
14.1.17.1 Business overview 366
14.1.17.2 Products & services offered 366
14.1.17.3 Recent developments 367
14.1.17.3.1 Product enhancements 367
14.1.18 ANSYS, INC. 368
14.1.18.1 Business overview 368
14.1.18.2 Products & services offered 369
14.1.18.3 Recent developments 369
14.1.18.3.1 Deals 369
14.1.18.3.2 Other developments 370
?
14.2 START-UP/SME PLAYERS 371
14.2.1 INSTEM GROUP OF COMPANIES 371
14.2.2 INSILICO MEDICINE 372
14.2.3 SCM – SOFTWARE CHEMISTRY & MATERIALS 373
14.2.4 BIOSYMETRICS, INC. 373
14.2.5 ATOMWISE INC. 374
14.2.6 INSITRO 374
14.2.7 CLINITHINK 375
15 APPENDIX 376
15.1 DISCUSSION GUIDE 376
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 382
15.3 CUSTOMIZATION OPTIONS 384
15.4 RELATED REPORTS 384
15.5 AUTHOR DETAILS 385



List of Figures

FIGURE 1 BIOSIMULATION MARKET SEGMENTATION & REGIONAL SCOPE 37
FIGURE 2 RESEARCH DESIGN 42
FIGURE 3 PRIMARY SOURCES 45
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 47
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 48
FIGURE 6 TOP-DOWN APPROACH 49
FIGURE 7 CAGR PROJECTIONS, 2024–2029 50
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 51
FIGURE 9 DATA TRIANGULATION 52
FIGURE 10 BIOSIMULATION MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION) 55
FIGURE 11 BIOSIMULATION MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION) 56
FIGURE 12 BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024 VS. 2029 (USD MILLION) 56
FIGURE 13 BIOSIMULATION MARKET, BY REVENUE MODEL, 2024 VS. 2029 (USD MILLION) 57
FIGURE 14 BIOSIMULATION MARKET, BY DEPLOYMENT MODEL 2024 VS. 2029 (USD MILLION) 58
FIGURE 15 BIOSIMULATION MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 59
FIGURE 16 GEOGRAPHIC SNAPSHOT OF BIOSIMULATION MARKET 60
FIGURE 17 INCREASING R&D EXPENDITURE ON DRUG DISCOVERY & DEVELOPMENT
BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DRIVE MARKET 61
FIGURE 18 CHINA DOMINATED MARKET IN ASIA PACIFIC IN 2023 62
FIGURE 19 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 63
FIGURE 20 NORTH AMERICA TO DOMINATE BIOSIMULATION MARKET DURING
FORECAST PERIOD 63
FIGURE 21 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES
DURING FORECAST PERIOD 64
FIGURE 22 BIOSIMULATION MARKET: DRIVERS, RESTRAINTS OPPORTUNITIES, AND CHALLENGES 65
FIGURE 23 BIOSIMULATION MARKET: ECOSYSTEM ANALYSIS 71
FIGURE 24 BIOSIMULATION MARKET: VALUE CHAIN ANALYSIS 74
FIGURE 25 BIOSIMULATION MARKET: PORTER’S FIVE FORCES ANALYSIS 76
FIGURE 26 BIOSIMULATION-RELATED PATENT APPLICATIONS AND
PUBLICATIONS, 2015–2024 83
FIGURE 27 BIOSIMULATION MARKET: PATENT ANALYSIS, JANUARY 2015–DECEMBER 2024 84
FIGURE 28 INDICATIVE PRICING ANALYSIS FOR BIOSIMULATION SOFTWARE 87
FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS 88
FIGURE 30 KEY BUYING CRITERIA FOR TOP 3 END USERS 89
FIGURE 31 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 90
FIGURE 32 BIOSIMULATION MARKET: INVESTMENT AND FUNDING SCENARIO FOR SMES 92
FIGURE 33 MARKET POTENTIAL OF AI/GENERATIVE AI ON BIOSIMULATION 93
FIGURE 34 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 94
FIGURE 35 NORTH AMERICA: BIOSIMULATION MARKET SNAPSHOT 165
FIGURE 36 ASIA PACIFIC: BIOSIMULATION MARKET SNAPSHOT 223
FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN BIOSIMULATION MARKET 2019–2023 (USD BILLION) 293
FIGURE 38 BIOSIMULATION MARKET: MARKET SHARE ANALYSIS (2023) 294
FIGURE 39 RANKING OF KEY PLAYERS IN BIOSIMULATION MARKET, 2023 296
FIGURE 40 BIOSIMULATION MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 298
FIGURE 41 BIOSIMULATION MARKET: COMPANY FOOTPRINT 299
FIGURE 42 BIOSIMULATION MARKET: COMPANY EVALUATION MATRIX
(START-UPS/SMES), 2023 305
FIGURE 43 EV/EBITDA OF KEY VENDORS, 2025 308
FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA
VALUE FOR BIOSIMULATION VENDORS 308
FIGURE 45 BIOSIMULATION MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 309
FIGURE 46 CERTARA, USA: COMPANY SNAPSHOT (2023) 314
FIGURE 47 DASSAULT SYST?MES: COMPANY SNAPSHOT (2023) 320
FIGURE 48 SCHR?DINGER, INC.: COMPANY SNAPSHOT (2023) 326
FIGURE 49 SIMULATIONS PLUS: COMPANY SNAPSHOT (2023) 332
FIGURE 50 GENEDATA AG (A DANAHER COMPANY): COMPANY SNAPSHOT (2023) 346
FIGURE 51 PHYSIOMICS PLC: COMPANY SNAPSHOT (2023) 348
FIGURE 52 OPENEYE, CADENCE MOLECULAR SCIENCES: COMPANY SNAPSHOT (2023) 355
FIGURE 53 ANSYS, INC.: COMPANY SNAPSHOT (2023) 368

List of Tables

TABLE 1 BIOSIMULATION MARKET: ROLE OF COMPANIES IN ECOSYSTEM 71
TABLE 2 BIOSIMULATION MARKET: PORTER’S FIVE FORCES 76
TABLE 3 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 80
TABLE 4 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 81
TABLE 5 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 81
TABLE 6 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 82
TABLE 7 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT
AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 8 INDICATIVE PRICING ANALYSIS OF KEY PLAYERS, BY OFFERING 87
TABLE 9 BIOSIMULATION MARKET: KEY CONFERENCES AND EVENTS, 2024–2025 88
TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS (%) 89
TABLE 11 KEY BUYING CRITERIA FOR TOP 3 END USERS 89
TABLE 12 UNMET NEEDS IN BIOSIMULATION MARKET 90
TABLE 13 END-USER EXPECTATIONS IN BIOSIMULATION MARKET 91
TABLE 14 BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 99
TABLE 15 BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION) 100
TABLE 16 BIOSIMULATION SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 100
TABLE 17 BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE 2022–2029 (USD MILLION) 101
TABLE 18 BIOSIMULATION MARKET FOR STANDALONE MODULES, BY COUNTRY 2022–2029 (USD MILLION) 102
TABLE 19 BIOSIMULATION MARKET FOR MOLECULAR MODELING & SIMULATION
SOFTWARE, BY COUNTRY, 2022–2029 (USD MILLION) 103
TABLE 20 BIOSIMULATION MARKET FOR PK/PD MODELING & SIMULATION SOFTWARE BY COUNTRY, 2022–2029 (USD MILLION) 104
TABLE 21 BIOSIMULATION MARKET FOR PBPK MODELING & SIMULATION SOFTWARE BY COUNTRY, 2022–2029 (USD MILLION) 105
TABLE 22 BIOSIMULATION MARKET FOR TOXICITY PREDICTION SOFTWARE, BY COUNTRY, 2022–2029 (USD MILLION) 106
TABLE 23 BIOSIMULATION MARKET FOR CLINICAL TRIAL SIMULATION SOFTWARE BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 24 BIOSIMULATION MARKET FOR OTHER BIOSIMULATION SOFTWARE BY COUNTRY, 2022–2029 (USD MILLION) 108
TABLE 25 BIOSIMULATION MARKET FOR INTEGRATED SOFTWARE SUITES/PLATFORMS BY COUNTRY, 2022–2029 (USD MILLION) 109
TABLE 26 BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 110
TABLE 27 BIOSIMULATION SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 110
TABLE 28 BIOSIMULATION MARKET FOR CONSULTING & ADVISORY SERVICES BY COUNTRY, 2022–2029 (USD MILLION) 111
TABLE 29 BIOSIMULATION MARKET FOR IMPLEMENTATION, TRAINING, AND SUPPORT SERVICES, BY COUNTRY, 2022–2029 (USD MILLION) 112
TABLE 30 BIOSIMULATION MARKET FOR DATA ANALYSIS & INTERPRETATION SERVICES BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 31 BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 115
TABLE 32 BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE 2022–2029 (USD MILLION) 116
TABLE 33 BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 116
TABLE 34 BIOSIMULATION MARKET FOR TARGET IDENTIFICATION & VALIDATION BY COUNTRY, 2022–2029 (USD MILLION) 117
TABLE 35 BIOSIMULATION MARKET FOR LEAD IDENTIFICATION & OPTIMIZATION BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 36 BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS BY TYPE, 2022–2029 (USD MILLION) 119
TABLE 37 BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 38 BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE 2022–2029 (USD MILLION) 121
TABLE 39 BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY COUNTRY 2022–2029 (USD MILLION) 121
TABLE 40 BIOSIMULATION MARKET FOR PK/PD, BY COUNTRY, 2022–2029 (USD MILLION) 122
TABLE 41 BIOSIMULATION MARKET FOR ADME/TOXICOLOGY, BY COUNTRY 2022–2029 (USD MILLION) 123
TABLE 42 BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE 2022–2029 (USD MILLION) 124
TABLE 43 BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY COUNTRY 2022–2029 (USD MILLION) 125
TABLE 44 BIOSIMULATION MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY 2022–2029 (USD MILLION) 126
TABLE 45 BIOSIMULATION MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY 2022–2029 (USD MILLION) 127
TABLE 46 BIOSIMULATION MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY 2022–2029 (USD MILLION) 128
TABLE 47 BIOSIMULATION MARKET FOR PHASE IV/POST-MARKETING SURVEILLANCE BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 48 BIOSIMULATION MARKET FOR DISEASE MODELING APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 130
TABLE 49 BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 131
TABLE 50 BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 131
TABLE 51 BIOSIMULATION MARKET FOR PRODUCTION PLANNING & OPTIMIZATION BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 52 BIOSIMULATION MARKET FOR QUALITY CONTROL & PROCESS MONITORING BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 53 BIOSIMULATION MARKET FOR DEMAND FORECASTING & INVENTORY MANAGEMENT, BY COUNTRY, 2022–2029 (USD MILLION) 134
TABLE 54 BIOSIMULATION MARKET FOR RISK MANAGEMENT & CONTINGENCY PLANNING, BY COUNTRY, 2022–2029 (USD MILLION) 135
TABLE 55 BIOSIMULATION MARKET FOR OTHER MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 136
TABLE 56 BIOSIMULATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY 2022–2029 (USD MILLION) 137
TABLE 57 BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 139
TABLE 58 BIOSIMULATION MARKET FOR ONCOLOGY, BY COUNTRY 2022–2029 (USD MILLION) 140
TABLE 59 BIOSIMULATION MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY 2022–2029 (USD MILLION) 141
TABLE 60 BIOSIMULATION MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY 2022–2029 (USD MILLION) 142
TABLE 61 BIOSIMULATION MARKET FOR INFECTIOUS DISEASES, BY COUNTRY 2022–2029 (USD MILLION) 143
TABLE 62 BIOSIMULATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY 2022–2029 (USD MILLION) 144
TABLE 63 BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION) 146
TABLE 64 BIOSIMULATION MARKET FOR LICENSE-BASED MODELS, BY COUNTRY 2022–2029 (USD MILLION) 147
TABLE 65 BIOSIMULATION MARKET FOR SUBSCRIPTION-BASED MODELS, BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 66 BIOSIMULATION MARKET FOR SERVICE-BASED MODELS, BY COUNTRY 2022–2029 (USD MILLION) 149
TABLE 67 BIOSIMULATION MARKET FOR PAY-PER-USE MODELS, BY COUNTRY 2022–2029 (USD MILLION) 150
TABLE 68 BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION) 152
TABLE 69 BIOSIMULATION MARKET FOR ON-PREMISE MODELS, BY COUNTRY 2022–2029 (USD MILLION) 153
TABLE 70 BIOSIMULATION MARKET FOR CLOUD-BASED MODELS, BY COUNTRY 2022–2029 (USD MILLION) 154
TABLE 71 BIOSIMULATION MARKET FOR HYBRID MODELS, BY COUNTRY 2022–2029 (USD MILLION) 155
TABLE 72 BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION) 157
TABLE 73 BIOSIMULATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 158
TABLE 74 BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS BY COUNTRY, 2022–2029 (USD MILLION) 159
TABLE 75 BIOSIMULATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION) 160
TABLE 76 BIOSIMULATION MARKET FOR REGULATORY BODIES, BY COUNTRY 2022–2029 (USD MILLION) 161
TABLE 77 BIOSIMULATION MARKET FOR OTHER END USERS, BY COUNTRY 2022–2029 (USD MILLION) 162
TABLE 78 BIOSIMULATION MARKET, BY REGION, 2022–2029 (USD MILLION) 164
TABLE 79 NORTH AMERICA: BIOSIMULATION MARKET, BY COUNTRY 2022–2029 (USD MILLION) 165
TABLE 80 NORTH AMERICA: BIOSIMULATION MARKET, BY OFFERING 2022–2029 (USD MILLION) 166
TABLE 81 NORTH AMERICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE 2022–2029 (USD MILLION) 166
TABLE 82 NORTH AMERICA: BIOSIMULATION MARKET FOR STANDALONE MODULES BY TYPE, 2022–2029 (USD MILLION) 166
TABLE 83 NORTH AMERICA: BIOSIMULATION SERVICES MARKET, BY TYPE 2022–2029 (USD MILLION) 167
TABLE 84 NORTH AMERICA: BIOSIMULATION MARKET, BY APPLICATION 2022–2029 (USD MILLION) 167
TABLE 85 NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 167
TABLE 86 NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 168
TABLE 87 NORTH AMERICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION) 168
TABLE 88 NORTH AMERICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE 2022–2029 (USD MILLION) 168
TABLE 89 NORTH AMERICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 169
TABLE 90 NORTH AMERICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 169
TABLE 91 NORTH AMERICA: BIOSIMULATION MARKET, BY REVENUE MODEL 2022–2029 (USD MILLION) 170
TABLE 92 NORTH AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL 2022–2029 (USD MILLION) 170
TABLE 93 NORTH AMERICA: BIOSIMULATION MARKET, BY END USER 2022–2029 (USD MILLION) 170
TABLE 94 US: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 172
TABLE 95 US: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION) 172
TABLE 96 US: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE 2022–2029 (USD MILLION) 172
TABLE 97 US: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 173
TABLE 98 US: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 173
TABLE 99 US: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS BY TYPE, 2022–2029 (USD MILLION) 173
TABLE 100 US: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS BY TYPE, 2022–2029 (USD MILLION) 174
TABLE 101 US: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE 2022–2029 (USD MILLION) 174
TABLE 102 US: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE 2022–2029 (USD MILLION) 174
TABLE 103 US: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 175
TABLE 104 US: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 175
TABLE 105 US: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION) 176
TABLE 106 US: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL 2022–2029 (USD MILLION) 176
TABLE 107 US: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION) 176
TABLE 108 CANADA: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 177
TABLE 109 CANADA: BIOSIMULATION SOFTWARE MARKET, BY TYPE 2022–2029 (USD MILLION) 177
TABLE 110 CANADA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE 2022–2029 (USD MILLION) 178
TABLE 111 CANADA: BIOSIMULATION SERVICES MARKET, BY TYPE 2022–2029 (USD MILLION) 178
TABLE 112 CANADA: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 179
TABLE 113 CANADA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS BY TYPE, 2022–2029 (USD MILLION) 179
TABLE 114 CANADA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS BY TYPE, 2022–2029 (USD MILLION) 179
TABLE 115 CANADA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE 2022–2029 (USD MILLION) 180
TABLE 116 CANADA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE 2022–2029 (USD MILLION) 180
TABLE 117 CANADA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 181
TABLE 118 CANADA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 181
TABLE 119 CANADA: BIOSIMULATION MARKET, BY REVENUE MODEL 2022–2029 (USD MILLION) 182
TABLE 120 CANADA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL 2022–2029 (USD MILLION) 182
TABLE 121 CANADA: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION) 182
TABLE 122 EUROPE: BIOSIMULATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 183
TABLE 123 EUROPE: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 183
TABLE 124 EUROPE: BIOSIMULATION SOFTWARE MARKET, BY TYPE 2022–2029 (USD MILLION) 184
TABLE 125 EUROPE: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE 2022–2029 (USD MILLION) 184
TABLE 126 EUROPE: BIOSIMULATION SERVICES MARKET, BY TYPE 2022–2029 (USD MILLION) 185
TABLE 127 EUROPE: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 185
TABLE 128 EUROPE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS BY TYPE, 2022–2029 (USD MILLION) 185
TABLE 129 EUROPE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS BY TYPE, 2022–2029 (USD MILLION) 186
TABLE 130 EUROPE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE 2022–2029 (USD MILLION) 186
TABLE 131 EUROPE: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE 2022–2029 (USD MILLION) 186
TABLE 132 EUROPE: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 187
TABLE 133 EUROPE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 187
TABLE 134 EUROPE: BIOSIMULATION MARKET, BY REVENUE MODEL 2022–2029 (USD MILLION) 188
TABLE 135 EUROPE: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL 2022–2029 (USD MILLION) 188
TABLE 136 EUROPE: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION) 188
TABLE 137 GERMANY: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 190
TABLE 138 GERMANY: BIOSIMULATION SOFTWARE MARKET, BY TYPE 2022–2029 (USD MILLION) 190
TABLE 139 GERMANY: BIOSIMULATION MARKET FOR STANDALONE MODULES BY TYPE, 2022–2029 (USD MILLION) 190
TABLE 140 GERMANY: BIOSIMULATION SERVICES MARKET, BY TYPE 2022–2029 (USD MILLION) 191
TABLE 141 GERMANY: BIOSIMULATION MARKET, BY APPLICATION 2022–2029 (USD MILLION) 191
TABLE 142 GERMANY: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS BY TYPE, 2022–2029 (USD MILLION) 191
TABLE 143 GERMANY: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS BY TYPE, 2022–2029 (USD MILLION) 192
TABLE 144 GERMANY: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE 2022–2029 (USD MILLION) 192
TABLE 145 GERMANY: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE 2022–2029 (USD MILLION) 192
TABLE 146 GERMANY: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 193
TABLE 147 GERMANY: BIOSIMULATION MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 193
TABLE 148 GERMANY: BIOSIMULATION MARKET, BY REVENUE MODEL 2022–2029 (USD MILLION) 194
TABLE 149 GERMANY: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL 2022–2029 (USD MILLION) 194
TABLE 150 GERMANY: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION) 194
TABLE 151 UK: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 195
TABLE 152 UK: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION) 195
TABLE 153 UK: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE 2022–2029 (USD MILLION) 196
TABLE 154 UK: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 196
TABLE 155 UK: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 197
TABLE 156 UK: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 197
TABLE 157 UK: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS BY TYPE, 2022–2029 (USD MILLION) 197
TABLE 158 UK: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE 2022–2029 (USD MILLION) 198
TABLE 159 UK: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE 2022–2029 (USD MILLION) 198
TABLE 160 UK: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 198
TABLE 161 UK: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 199
TABLE 162 UK: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION) 199
TABLE 163 UK: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL 2022–2029 (USD MILLION) 199
TABLE 164 UK: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION) 200
TABLE 165 FRANCE: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 201
TABLE 166 FRANCE: BIOSIMULATION SOFTWARE MARKET, BY TYPE 2022–2029 (USD MILLION) 201
TABLE 167 FRANCE: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE 2022–2029 (USD MILLION) 201
TABLE 168 FRANCE: BIOSIMULATION SERVICES MARKET, BY TYPE 2022–2029 (USD MILLION) 202
TABLE 169 FRANCE: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 202
TABLE 170 FRANCE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 202
TABLE 171 FRANCE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS BY TYPE, 2022–2029 (USD MILLION) 203
TABLE 172 FRANCE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE 2022–2029 (USD MILLION) 203
TABLE 173 FRANCE: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE 2022–2029 (USD MILLION) 203
TABLE 174 FRANCE: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 204
TABLE 175 FRANCE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 204
TABLE 176 FRANCE: BIOSIMULATION MARKET, BY REVENUE MODEL 2022–2029 (USD MILLION) 205
TABLE 177 FRANCE: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL 2022–2029 (USD MILLION) 205
TABLE 178 FRANCE: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION) 205
TABLE 179 ITALY: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 206
TABLE 180 ITALY: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION) 206
TABLE 181 ITALY: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE 2022–2029 (USD MILLION) 207
TABLE 182 ITALY: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 207
TABLE 183 ITALY: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 208
TABLE 184 ITALY: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS BY TYPE, 2022–2029 (USD MILLION) 208
TABLE 185 ITALY: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS BY TYPE, 2022–2029 (USD MILLION) 208
TABLE 186 ITALY: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE 2022–2029 (USD MILLION) 209
TABLE 187 ITALY: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE 2022–2029 (USD MILLION) 209
TABLE 188 ITALY: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 209
TABLE 189 ITALY: BIOSIMULATION MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 210
TABLE 190 ITALY: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION) 210
TABLE 191 ITALY: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL 2022–2029 (USD MILLION) 210
TABLE 192 ITALY: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION) 211
TABLE 193 SPAIN: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 212
TABLE 194 SPAIN: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION) 212
TABLE 195 SPAIN: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE 2022–2029 (USD MILLION) 212
TABLE 196 SPAIN: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 213
TABLE 197 SPAIN: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 213
TABLE 198 SPAIN: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS BY TYPE, 2022–2029 (USD MILLION) 213
TABLE 199 SPAIN: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS BY TYPE, 2022–2029 (USD MILLION) 214
TABLE 200 SPAIN: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE 2022–2029 (USD MILLION) 214
TABLE 201 SPAIN: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE 2022–2029 (USD MILLION) 214
TABLE 202 SPAIN: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 215
TABLE 203 SPAIN: BIOSIMULATION MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 215
TABLE 204 SPAIN: BIOSIMULATION MARKET, BY REVENUE MODEL 2022–2029 (USD MILLION) 216
TABLE 205 SPAIN: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL 2022–2029 (USD MILLION) 216
TABLE 206 SPAIN: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION) 216
TABLE 207 REST OF EUROPE: BIOSIMULATION MARKET, BY OFFERING 2022–2029 (USD MILLION) 217
TABLE 208 REST OF EUROPE: BIOSIMULATION SOFTWARE MARKET, BY TYPE 2022–2029 (USD MILLION) 217
TABLE 209 REST OF EUROPE: BIOSIMULATION MARKET FOR STANDALONE MODULES BY TYPE, 2022–2029 (USD MILLION) 218
TABLE 210 REST OF EUROPE: BIOSIMULATION SERVICES MARKET, BY TYPE 2022–2029 (USD MILLION) 218
TABLE 211 REST OF EUROPE: BIOSIMULATION MARKET, BY APPLICATION 2022–2029 (USD MILLION) 219
TABLE 212 REST OF EUROPE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 219
TABLE 213 REST OF EUROPE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 219
TABLE 214 REST OF EUROPE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING BY TYPE, 2022–2029 (USD MILLION) 220
TABLE 215 REST OF EUROPE: BIOSIMULATION MARKET FOR CLINICAL TRIALS BY TYPE, 2022–2029 (USD MILLION) 220
TABLE 216 REST OF EUROPE: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 220
TABLE 217 REST OF EUROPE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 221
TABLE 218 REST OF EUROPE: BIOSIMULATION MARKET, BY REVENUE MODEL 2022–2029 (USD MILLION) 221
TABLE 219 REST OF EUROPE: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL 2022–2029 (USD MILLION) 221
TABLE 220 REST OF EUROPE: BIOSIMULATION MARKET, BY END USER 2022–2029 (USD MILLION) 222
TABLE 221 ASIA PACIFIC: BIOSIMULATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 224
TABLE 222 ASIA PACIFIC: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 224
TABLE 223 ASIA PACIFIC: BIOSIMULATION SOFTWARE MARKET, BY TYPE 2022–2029 (USD MILLION) 224
TABLE 224 ASIA PACIFIC: BIOSIMULATION MARKET FOR STANDALONE MODULES BY TYPE, 2022–2029 (USD MILLION) 225
TABLE 225 ASIA PACIFIC: BIOSIMULATION SERVICES MARKET, BY TYPE 2022–2029 (USD MILLION) 225
TABLE 226 ASIA PACIFIC: BIOSIMULATION MARKET, BY APPLICATION 2022–2029 (USD MILLION) 225
TABLE 227 ASIA PACIFIC: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS BY TYPE, 2022–2029 (USD MILLION) 226
TABLE 228 ASIA PACIFIC: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 226
TABLE 229 ASIA PACIFIC: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION) 226
TABLE 230 ASIA PACIFIC: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE 2022–2029 (USD MILLION) 227
TABLE 231 ASIA PACIFIC: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 227
TABLE 232 ASIA PACIFIC: BIOSIMULATION MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 228
TABLE 233 ASIA PACIFIC: BIOSIMULATION MARKET, BY REVENUE MODEL 2022–2029 (USD MILLION) 228
TABLE 234 ASIA PACIFIC: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL 2022–2029 (USD MILLION) 228
TABLE 235 ASIA PACIFIC: BIOSIMULATION MARKET, BY END USER 2022–2029 (USD MILLION) 229
TABLE 236 CHINA: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 230
TABLE 237 CHINA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION) 230
TABLE 238 CHINA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE 2022–2029 (USD MILLION) 231
TABLE 239 CHINA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 231
TABLE 240 CHINA: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 231
TABLE 241 CHINA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 232
TABLE 242 CHINA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS BY TYPE, 2022–2029 (USD MILLION) 232
TABLE 243 CHINA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE 2022–2029 (USD MILLION) 232
TABLE 244 CHINA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE 2022–2029 (USD MILLION) 233
TABLE 245 CHINA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 233
TABLE 246 CHINA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 234
TABLE 247 CHINA: BIOSIMULATION MARKET, BY REVENUE MODEL 2022–2029 (USD MILLION) 234
TABLE 248 CHINA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL 2022–2029 (USD MILLION) 234
TABLE 249 CHINA: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION) 235
TABLE 250 INDIA: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 236
TABLE 251 INDIA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION) 236
TABLE 252 INDIA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE 2022–2029 (USD MILLION) 236
TABLE 253 INDIA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 237
TABLE 254 INDIA: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 237
TABLE 255 INDIA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 237
TABLE 256 INDIA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS BY TYPE, 2022–2029 (USD MILLION) 238
TABLE 257 INDIA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE 2022–2029 (USD MILLION) 238
TABLE 258 INDIA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE 2022–2029 (USD MILLION) 238
TABLE 259 INDIA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 239
TABLE 260 INDIA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 239
TABLE 261 INDIA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION) 240
TABLE 262 INDIA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL 2022–2029 (USD MILLION) 240
TABLE 263 INDIA: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION) 240
TABLE 264 JAPAN: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION) 241
TABLE 265 JAPAN: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION) 241
TABLE 266 JAPAN: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE 2022–2029 (USD MILLION) 242
TABLE 267 JAPAN: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 242
TABLE 268 JAPAN: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 242
TABLE 269 JAPAN: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 243
TABLE 270 JAPAN: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS BY TYPE, 2022–2029 (USD MILLION) 243
TABLE 271 JAPAN: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE 2022–2029 (USD MILLION) 243
TABLE 272 JAPAN: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE 2022–2029 (USD MILLION) 244
TABLE 273 JAPAN: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 244
TABLE 274 JAPAN: BIOSIMULATION MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 245
TABLE 275 JAPAN: BIOSIMULATION MARKET, BY REVENUE MODEL 2022–2029 (USD MILLION) 245
TABLE 276 JAPAN: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL 2022–2029 (USD MILLION) 245
TABLE 277 JAPAN: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION) 246
TABLE 278 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY OFFERING 2022–2029 (USD MILLION) 246
TABLE 279 REST OF ASIA PACIFIC: BIOSIMULATION SOFTWARE MARKET, BY TYPE 2022&ndash